GleamWall
中文EN

TYRA Tyra Biosciences, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1863127 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-52.1%
TTM EPS YoY-39.9%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-34.9%
ROA-33.0%
ROIC (approx.)-63.3%
Asset turnover—

Leverage & solvency

Liabilities / assets4.8%
Debt / equity0.00x
Current ratio23.93x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.70x
Accruals ratio-9.8%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue——
R&D expense$102.93M$80.08M
SG&A expense$29.83M$24.10M
Operating income-$132.76M-$104.18M
Income tax$0$0
Net income-$119.95M-$86.48M
EBITDA-$132.22M-$103.66M
EPS (basic)-2.01-1.51
EPS (diluted)-2.01-1.51
Weighted avg. shares (diluted)59.60M57.22M
Balance sheet
Cash & equivalents$77.39M$92.97M
Current assets$265.45M$347.46M
PP&E, net$1.31M$1.65M
Total assets$282.61M$363.56M
Current liabilities$18.09M$14.59M
Total liabilities$23.43M$20.41M
Shareholders' equity$259.18M$343.15M
Shares outstanding53.71M50.75M
Cash flow statement
Operating cash flow-$95.14M-$69.77M
Capital expenditure$141,000$664,000
Free cash flow-$95.28M-$70.44M
Investing cash flow$72.46M-$98.40M
Financing cash flow$8.10M$202.14M
Depreciation & amortization$546,000$519,000
Stock-based compensation$28.01M$22.80M

Free plan shows the latest 2 periods; Pro shows all 6 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.